ValueAct Capital Buys More Valeant Pharmaceuticals | Value Investing News

ValueAct Capital Buys More Valeant Pharmaceuticals

  • Jeff Ubben's activist firm ValueAct Capital has filed a 13D and Form 4 with the SEC regarding its position in Valeant Pharmaceuticals.
  • Per the 13D, ValueAct now owns 5.2% of the company with over 17.99 million shares.
  • They purchased 3 million shares in total on March 14th, with the bulk of the trade coming at $10.81 per share with some shares coming at $10.88.
Rating: 
No votes yet
Article Link: 
Shared Count: 
0
Value Score: 
0
Category: